Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Imipramine may relieve dyspepsia symptoms in Asians with poor response to PPIs, prokinetics

Roshini Claire Anthony
27 Nov 2018

Patients with inadequate response to proton pump inhibitors and prokinetics for functional dyspepsia may derive benefit from low doses of the tricyclic antidepressant (TCA) imipramine, according to a recent study from Hong Kong.

“This … trial showed that 12 weeks of treatment with imipramine was efficacious for treatment-refractory functional dyspepsia,” said the researchers.

This single-centre, double-blind trial involved 107 adults of Chinese ethnicity who experienced moderate symptoms of functional dyspepsia (Rome II) despite treatment with esomeprazole (20 mg once/day for 8 weeks) followed by domperidone (10 mg TID for 4 weeks). The patients were randomized to receive imipramine (50 mg once/night [initial dose of 25 mg once/night for 2 weeks]; n=55, mean age 46.4 years, 82 percent female) or placebo (n=52, mean age 46.0 years, 77 percent female) for 12 weeks. Patients were Helicobacter pylori-negative and had a normal upper gastrointestinal endoscopy and abdominal ultrasound. Eighty-one patients completed the trial, 40 and 41 in the imipramine and placebo groups, respectively (per-protocol population).

At 12 weeks, patients who received imipramine were more likely to experience relief of their dyspepsia symptoms compared with patients who received placebo (63.6 percent vs 36.5 percent; p=0.0051). The findings remained significant in the per-protocol analysis (70.0 percent vs 43.9 percent; p=0.018). [Lancet Gastroenterol Hepatol 2018;3:837-844]

At 12 weeks, placebo recipients did not experience significant reductions in mean scores from baseline for individual symptoms except for belching (p=0.012). Conversely, at 12 weeks, imipramine recipients experienced significant reductions from baseline in mean total dyspepsia symptom scores (p=0.0010), as well as scores for epigastric pain (p=0.026), bloating (p<0.0001), postprandial fullness (p=0.039), early satiety (p=0.0040), and vomiting (p=0.046).

The rate of treatment discontinuation due to adverse events (AEs) was higher among imipramine than placebo recipients (18 percent vs 8 percent). The 10 discontinuations in the imipramine group were due to dry mouth (n=3), constipation (n=2), drowsiness (n=2), insomnia (n=1), palpitations (n=1), and blurred vision (n=1), while the four discontinuations in the placebo group were due to dry mouth and constipation (n=1), palpitations (n=1), gastroesophageal reflux worsening (n=1), and limb paraesthesia (n=1).

The effect on sleep was comparable between patients on imipramine and placebo (p=0.24). At 12 weeks, patients on imipramine experienced improvements in mood as demonstrated with significant reductions in total Hospital Anxiety and Depression Scale (HADS) scores (p=0.049), with no apparent difference among patients on placebo.

According to the researchers, currently available treatments for functional dyspepsia are “far from satisfactory”.

“TCAs are a valuable addition to the therapeutic arsenal in functional dyspepsia, and further studies will elucidate the mechanism of action of these agents so that more potent drugs can be developed in the future,” said Drs Takeshi Kanno and Paul Moayyedi from McMaster University, Ontario, Canada, in a commentary. [Lancet Gastroenterol Hepatol 2018;doi:10.1016/S2468-1253(18)30338-8]

“AEs are minimized with the low doses used in patients with functional dyspepsia, but the risks and benefits of TCAs must be carefully discussed with the patient,” they advised.

While the AEs may be outweighed by the benefits of imipramine, the researchers also draw the line at recommending imipramine in the first-line setting or in generalizing the findings to other ethnicities.

The reduction in HADS scores suggest that the improvement in dyspepsia symptoms with imipramine may be influenced by improvements in mood, they noted, though the direction of the association could not be determined.

“Our findings further highlight the complex relationship between mood and dyspeptic symptoms and suggest that … behavioural therapy could also have a role in the management of functional dyspepsia,” they said.

The higher withdrawal rate due to AEs among imipramine recipients suggests that TCAs may not be suitable for all patients with functional dyspepsia, they added.

“Clinicians should [also] be aware that patients with functional dyspepsia might be reluctant to take antidepressants, and it should be emphasized that TCAs are being prescribed for their action on the digestive tract and not for their psychiatric effects,” said Kanno and Moayyedi.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.